Independent Analyses To Inform Go/No-go Decisions

Independent AnalysesOur client in this case was an investment organization specialized in biotechnology companies, and they required an urgent analysis of clinical data that would be presented on the following week to key decision-makers in the acquisition of a new biotechnology product. The manufacturer of the product had conducted a phase III trial and published the results, but the contract research organization that performed the original statistical analysis was no longer able to provide support to our client. Moreover, there was a need to verify the original results, given the fact that they were negative in the overall trial population, but provided signals of activity in subgroups. By repeating the analysis in only six days and questioning some of the original results presented by the manufacturer in their publication, IDDI was able to better inform their decision-making process.